Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696546 | 1.00 | HRH4 (0.38) | HRH4CXCR4HRH3CCR4DGAT2 | |
| SCHEMBL2009395 | 0.93 | CXCR4 (0.38) | HRH4CXCR4HRH3CCR4DGAT2 | |
| SCHEMBL4116289 | 0.92 | HRH4 (0.38) | HRH4CXCR4HRH3CCR4DGAT2 | |
| SCHEMBL2013989 | 0.91 | HRH4 (0.36) | HRH4CXCR4HRH3CCR4 | |
| SCHEMBL13696549 | 0.91 | HRH4 (0.36) | HRH4CXCR4HRH3CCR4 | |
| SCHEMBL13696548 | 0.86 | HRH4 (0.37) | HRH4CXCR4HRH3CCR4DGAT2 | |
| SCHEMBL2012279 | 0.86 | HRH4 (0.37) | HRH4CXCR4HRH3CCR4DGAT2 | |
| SCHEMBL4105443 | 0.84 | HRH4 (0.41) | HRH4CXCR4HRH3 | |
| SCHEMBL2014328 | 0.84 | HRH4 (0.41) | HRH4CXCR4HRH3 | |
| SCHEMBL13696576 | 0.84 | HRH4 (0.41) | HRH4CXCR4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | claimed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | claimed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-7964191-B2 | Compositions and methods for the treatment of ophthalmic disease | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | CXCR4, CXCR1, CXCL12 | HRH4 152/4885CXCR4 1/4885HRH3 158/4885 |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | CXCL12, CXCR4, PDE6C | HRH4 2600/4885CXCR4 2/4885HRH3 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.